We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




bioMérieux Acquires Molecular Diagnostics Provider Argene

By LabMedica International staff writers
Posted on 21 Jul 2011
bioMérieux SA (Marcy l'Etoile, France), a company specializing in in-vitro diagnostics, acquired Argene SA (Verniolle, France) for US$60.1 million. More...
Argene, a molecular diagnostics provider, is bioMérieux's tenth acquisition in the last five years.

Argene provides a wide range of diagnostics for infectious diseases, including quantitative tests for Cytomegalovirus, Epstein-Barr virus, and herpes simplex virus types 1 and 2. These tests are available for use on most commercial, open real-time polymerase chain reaction (PCR) platforms.

“Argene’s unique expertise and comprehensive range of diagnostics for immunocompromised patients will reinforce bioMérieux’s infectious disease offering in an important field of medicine. This acquisition will also enable us to accelerate the time to market of a broad test menu on the new molecular platform we are developing with Biocartis,” said Jean-Luc Bélingard, chairman and CEO of bioMérieux. “There is a perfect strategic fit between our companies and a shared commitment to improve patient health. We are very pleased that the Argene team will be joining bioMérieux,” he added.

Related Links:
bioMérieux
Argene


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.